Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

5.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.550
Bid (Size) 4.920 (1)
Ask (Size) 6.100 (5)
Prev. Close 5.550
Today's Range 5.550 - 5.550
52wk Range 4.020 - 43.12
Shares Outstanding 98,161,823
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
15 Analysts Have This to Say About Fate Therapeutics
 
Via Benzinga
FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
From The Rosen Law Firm, P.A.
Via Business Wire

Performance

YTD
-45.43%
-45.43%
1 Month
-7.65%
-7.65%
3 Month
-43.71%
-43.71%
6 Month
-75.97%
-75.97%
1 Year
-86.77%
-86.77%

More News

Read More
FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
From The Law Offices of Frank R. Cruz
Via Business Wire
Expert Ratings for Fate Therapeutics
Via Benzinga
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:FATE Investor Notice: Deadline on March 22, 2023 in Lawsuit Against Fate Therapeutics, Inc
Via SBWire
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Days to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, A LEADING NATIONAL FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE
From The Rosen Law Firm PA
Via Globe NewsWire
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via Globe NewsWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via Globe NewsWire
FATE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, A GLOBAL AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Loses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
ROSEN, A RANKED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
From Pomerantz LLP
Via Globe NewsWire
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.